

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 1)\*

**CAMP4 THERAPEUTICS CORPORATION**

---

(Name of Issuer)

**Common Stock, par value \$0.0001 per share**

---

(Title of Class of Securities)

**13463J101**

---

(CUSIP Number)

**09/30/2025**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

CUSIP No. 13463J101

Names of Reporting Persons

1

AH Bio Fund I, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

- (a)  
 (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power
5	1,579,885.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	1,579,885.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,579,885.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	3.4 %
12	Type of Reporting Person (See Instructions)
	PN

## SCHEDULE 13G

**CUSIP No.** 13463J101

1	Names of Reporting Persons
	AH Equity Partners Bio I, L.L.C.
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	1,579,885.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	1,579,885.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,579,885.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>

11 Percent of class represented by amount in row (9)  
3.4 %  
Type of Reporting Person (See Instructions)  
12 OO

## SCHEDULE 13G

**CUSIP No.** 13463J101

Names of Reporting Persons

1 AH Bio Fund IV, L.P.  
Check the appropriate box if a member of a Group (see instructions)

2  (a)  
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 545,454.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 0.00

Sole Dispositive Power

7 545,454.00

8 Shared Dispositive Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 545,454.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11 1.2 %

Type of Reporting Person (See Instructions)

12 PN

## SCHEDULE 13G

**CUSIP No.** 13463J101

Names of Reporting Persons

1 AH Equity Partners Bio IV, L.L.C.

2 Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only  
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5

545,454.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6

0.00

Sole Dispositive Power

7

545,454.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

545,454.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

1.2 %

Type of Reporting Person (See Instructions)

12

OO

## SCHEDULE 13G

**CUSIP No.** 13463J101

Names of Reporting Persons

1

Marc L. Andreessen

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5

0.00

Shared Voting Power

6

2,125,339.00

Sole Dispositive Power

7

0.00

8 Shared Dispositive  
Power

2,125,339.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

2,125,339.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.5 %

Type of Reporting Person (See Instructions)

12

IN

### SCHEDULE 13G

CUSIP No. 13463J101

Names of Reporting Persons

1

Benjamin A. Horowitz

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of Shares

Shared Voting Power

6

Beneficially Owned by Each Reporting Person

2,125,339.00

Sole Dispositive Power

7

0.00

Reporting Person

Shared Dispositive

With:

8

Power

2,125,339.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

2,125,339.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.5 %

Type of Reporting Person (See Instructions)

12

IN

### SCHEDULE 13G

Item 1.

Name of issuer:

(a)

CAMP4 THERAPEUTICS CORPORATION

Address of issuer's principal executive offices:

(b)

One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, 02139.

Item 2.

Name of person filing:

(a)

The names of the persons filing this report (collectively, the "Reporting Persons") are: AH Bio Fund I, L.P. ("AH Bio I") AH Equity Partners Bio I, L.L.C. ("AH EP Bio I") AH Bio Fund IV, L.P. ("AH Bio IV") AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") Marc L. Andreessen ("Andreessen") Benjamin A. Horowitz ("Horowitz") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Address or principal business office or, if none, residence:

(b)

The address for each of the Reporting Persons is: Andreessen Horowitz 2865 Sand Hill Road, Suite 101 Menlo Park, CA 94025

Citizenship:

(c)

AH Bio I Delaware AH EP Bio I Delaware AH Bio IV Delaware AH EP Bio IV Delaware Andreessen United States Horowitz United States

Title of class of securities:

(d)

Common Stock, par value \$0.0001 per share

CUSIP No.:

(e)

13463J101

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 1,579,885 shares of common stock directly held by AH Bio I and (ii) 545,454 shares of common stock directly held by AH Bio IV. AH EP Bio I is the general partner of AH Bio I and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer held of record by AH Bio I for itself and as nominee for AH Bio Fund I-B, L.P. ("AH Bio I-B"). Andreessen and Horowitz are the managing members of AH EP Bio I and may be deemed to have shared power to vote and shared power to dispose of shares of the Issuer held of record by AH Bio I for itself and as nominee for AH Bio I-B. AH EP Bio IV is the general partner of AH Bio IV and may be deemed to have sole power to vote and sole power to dispose of the shares of the Issuer held of record by AH Bio IV for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P., and CLF Partners III, LP. Andreessen and Horowitz are the managing members of AH EP Bio IV and may be deemed to have shared power to vote and shared power to dispose of the shares of the Issuer held of record by AH Bio IV for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP.

(a)

(b) Percent of class:

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 46,880,185 shares of common stock outstanding as of September 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 6, 2025. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AH Bio Fund I, L.P.

Signature: /s/ Phil Hathaway

By AH Equity Partners Bio I, L.L.C., Its General  
Name/Title: Partner, By Phil Hathaway, Chief Operating  
Officer (See Note 1)

Date: 11/14/2025

AH Equity Partners Bio I, L.L.C.

Signature: /s/ Phil Hathaway  
Name/Title: By Phil Hathaway, Chief Operating Officer  
Date: 11/14/2025

AH Bio Fund IV, L.P.

Signature: /s/ Phil Hathaway  
By AH Equity Partners Bio IV, L.L.C., Its General  
Name/Title: Partner, By Phil Hathaway, Chief Operating  
Officer (See Note 2)  
Date: 11/14/2025

AH Equity Partners Bio IV, L.L.C.

Signature: /s/ Phil Hathaway  
Name/Title: By Phil Hathaway, Chief Operating Officer  
Date: 11/14/2025

Marc L. Andreessen

Signature: /s/ Phil Hathaway  
Name/Title: Phil Hathaway, Attorney-in-Fact for Marc L.  
Andreessen (See Note 3)  
Date: 11/14/2025

Benjamin A. Horowitz

Signature: /s/ Phil Hathaway  
Name/Title: Phil Hathaway, Attorney-in-Fact for Benjamin A.  
Horowitz (See Note 3)  
Date: 11/14/2025

**Comments accompanying signature:** Note 1: AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P. Note 2: AH Bio Fund IV, L.P. for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P., and CLF Partners III, LP. Note 3: Signed pursuant to a Power of Attorney already on file with the SEC.

#### **Exhibit Information**

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13G filed with the SEC on October 22, 2024).